Mark J. Caulfield

126.7k total citations · 9 hit papers
170 papers, 17.2k citations indexed

About

Mark J. Caulfield is a scholar working on Cardiology and Cardiovascular Medicine, Genetics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mark J. Caulfield has authored 170 papers receiving a total of 17.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Cardiology and Cardiovascular Medicine, 56 papers in Genetics and 53 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mark J. Caulfield's work include Hormonal Regulation and Hypertension (42 papers), Blood Pressure and Hypertension Studies (37 papers) and Genetic Associations and Epidemiology (29 papers). Mark J. Caulfield is often cited by papers focused on Hormonal Regulation and Hypertension (42 papers), Blood Pressure and Hypertension Studies (37 papers) and Genetic Associations and Epidemiology (29 papers). Mark J. Caulfield collaborates with scholars based in United Kingdom, United States and Sweden. Mark J. Caulfield's co-authors include Neil R Poulter, Peter Sever, Gordon T. McInnes, Eoin OʼBrien, Hans Wedel, Jesper Mehlsen, Sverre E. Kjeldsen, Markku S. Nieminen, Rory Collins and Arni Kristinsson and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Mark J. Caulfield

169 papers receiving 16.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

2003 2.7k citations Neil R Poulter, Hans Wedel et al. The Lancet profile →
Effects of Torcetrapib in Patients at High Risk for Coronary Events

2007 2.2k citations Mark J. Caulfield et al. profile →
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

2005 1.9k citations Neil R Poulter, Hans Wedel et al. The Lancet profile →
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people

2014 1.2k citations Eleni Rapsomaniki, Adam Timmis et al. The Lancet profile →
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

2015 735 citations Bryan Williams, Mark J. Caulfield et al. The Lancet profile →
Hypertension

2015 510 citations Neil R Poulter, Mark J. Caulfield et al. The Lancet profile →
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

2015 455 citations Mark J. Caulfield, Neil R Poulter et al. The Lancet profile →
Dietary Nitrate Provides Sustained Blood Pressure Lowering in Hypertensive Patients

2014 370 citations Vikas Kapil, Mark J. Caulfield et al. Hypertension profile →
Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy

2019 229 citations Marta Cześnikiewicz‐Guzik, Grzegorz Osmenda et al. European Heart Journal profile →

Peers

Countries citing papers authored by Mark J. Caulfield

Since Specialization

Citations

This map shows the geographic impact of Mark J. Caulfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Caulfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Caulfield more than expected).

Fields of papers citing papers by Mark J. Caulfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Caulfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Caulfield. The network helps show where Mark J. Caulfield may publish in the future.

Co-authorship network of co-authors of Mark J. Caulfield

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Caulfield. A scholar is included among the top collaborators of Mark J. Caulfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Caulfield. Mark J. Caulfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Genomics England haplotype reference panel and imputation of UK Biobank 2024 ·Nature Genetics ·Sinan Shi, Simone Rubinacci, Sile Hu, Loukas Moutsianas, Alexander Stuckey, Anna C. Need, Pier Francesco Palamara, Mark J. Caulfield, Jonathan Marchini, Simon Myers	9
2	UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment 2023 ·British Journal of Clinical Pharmacology ·Emma Magavern, Andrew W. Hitchings, (unknown), Kurt Wilson, David Hepburn, (unknown), Amir H. Sam, Mark J. Caulfield, Simon Maxwell	9
3	CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel 2023 ·JACC Advances ·Emma Magavern, Benjamin M. Jacobs, Helen R. Warren, Gherardo Finocchiaro, Sarah Finer, David A. van Heel, Damian Smedley, Mark J. Caulfield	13
4	Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank 2020 ·Journal of Public Health ·Zahra Raisi‐Estabragh, Celeste McCracken, (unknown), Jackie Cooper, Cyrus Cooper, Mark J. Caulfield, Patricia B. Munroe, Nicholas C. Harvey, Steffen E. Petersen	211
5	An online compendium of treatable genetic disorders 2020 ·American Journal of Medical Genetics Part C Seminars in Medical Genetics ·David Bick, (unknown), David Dimmock, Tom Fowler, Mark J. Caulfield, Richard H. Scott	43
6	Phospholemman Phosphorylation Regulates Vascular Tone, Blood Pressure, and Hypertension in Mice and Humans 2020 ·Circulation ·Andrii Boguslavskyi, Sergiy Tokar, Oleksandra Prysyazhna, Olena Rudyk, David Sánchez-Tatay, (unknown), Kim A. Dora, C J Garland, Helen R. Warren, Alex S. F. Doney, (unknown), Mark J. Caulfield, (unknown), J. W. Howie, William Fuller, Michael J. Shattock	12
7	Mendelian randomisation analyses find pulmonary factors mediate the effect of height on coronary artery disease 2019 ·Communications Biology ·Eirini Marouli, Fabiola Del Greco M, Christina M. Astley, Jian Yang, Shafqat Ahmad, Sonja I. Berndt, Mark J. Caulfield, Εvangelos Εvangelou, Barbara McKnight, Carolina Medina‐Gómez, Jana V. van Vliet‐Ostaptchouk, Helen R. Warren, Zhihong Zhu, Joel N. Hirschhorn, Ruth J. F. Loos, Zoltán Kutalik, Panos Deloukas	31
8	Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy breakdown → 2019 ·European Heart Journal ·Marta Cześnikiewicz‐Guzik, Grzegorz Osmenda, Mateusz Siedliński, (unknown), (unknown), (unknown), G. Wilk, T. Mikołajczyk, Agata Schramm‐Luc, (unknown), Paweł T. Matusik, Joanna Kozioł, M Dróźdź, (unknown), Maciej Tomaszewski, Εvangelos Εvangelou, Mark J. Caulfield, Tomasz Grodzicki, Francesco D’Aiuto, Tomasz J. Guzik	229
9	Randomised, double-blind, placebo-controlled study investigating the effects of inorganic nitrate on vascular function, platelet reactivity and restenosis in stable angina: protocol of the NITRATE-OCT study 2016 ·BMJ Open ·Krishnaraj S. Rathod, Daniel A. Jones, (unknown), (unknown), Helen R. Warren, Stephen Hamshere, Vikas Kapil, Ajay Jain, Andrew Deaner, Neil R Poulter, Mark J. Caulfield, Anthony Mathur, Amrita Ahluwalia	5
10	Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people breakdown → 2014 ·The Lancet ·Eleni Rapsomaniki, Adam Timmis, Julie George, Mar Pujades‐Rodríguez, Anoop D Shah, Spiros Denaxas, Ian R. White, Mark J. Caulfield, John Deanfield, Liam Smeeth, Bryan Williams, Aroon D. Hingorani, Harry Hemingway	1152
11	Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study 2011 ·The Lancet ·Kate Lovibond, Sue Jowett, Pelham Barton, Mark J. Caulfield, Carl Heneghan, Richard Hobbs, James Hodgkinson, Jonathan Mant, Una Martin, Bryan Williams, David Wonderling, Richard J. McManus	230
12	Association between variants of the human GSTM gene family and hypertension 2006 ·Hypertension ·Christian Delles, (unknown), Patricia B. Munroe, Sandosh Padmanabhan, (unknown), Nick J.R. Brain, Morris J. Brown, Nilesh J. Samani, D Clayton, Martin Farrall, John Webster, J. M. C. Connell, Mark J. Caulfield, Anna F. Dominiczak	1
13	Bases genéticas de la hipertensión arterial esencial en Colombia: avances en nueve años de estudio 2006 ·Revista Colombiana de Cardiología ·(unknown), Edwin García, Juan G. McEwen, Mark J. Caulfield, (unknown), Eduardo Medina, (unknown), (unknown)	6
14	The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb (ASCOT-BPLA): effects in patients with type 2 diabetes 2006 ·Diabetologia ·Jan Östergren, (unknown), N. Poulter, Björn Dahlöf, Hans Wedel, Gareth Beevers, Mark J. Caulfield, (unknown), SE Kjeldsen, Arni Kristinsson, GT McInnes, Jesper Mehlsen, Markku M. Nieminen, E T O'Brien	6
15	Enhanced support for linkage to chromosome 5q13.1 and hypertension in the British Genetics of Hypertension (BRIGHT) study. 2005 ·Hypertension ·Patricia B. Munroe, Chris Wallace, Charles A. Mein, Richard Dobson, Mei Xue, (unknown), Beverley Burke, Johannie Gungadoo, Abiodun Onipinla, Stephen Newhouse, J Pembroke, J Connell, Marc D. Brown, N. J. Samani, (unknown), Jennifer Webster, G.M. Lathrop, D Clayton, Martin Farrall, Mark J. Caulfield	1
16	Chromosome 2p shows genome wide significant linkage to of anti-hypertensive medication response in the British genetics of hypertension (BRIGHT) study. 2005 ·Hypertension ·Sandosh Padmanabhan, Chris Wallace, Patricia B. Munroe, M. J. Brown, N. J. Samani, D Clayton, Martin Farrall, Jennifer Webster, M Lathrop, Mark J. Caulfield, Anna F. Dominiczak, J. M. C. Connell	3
17	Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension study 2005 ·Human Molecular Genetics ·Stephen Newhouse, Chris Wallace, Richard Dobson, Charles A. Mein, J Pembroke, Martin Farrall, David Clayton, Morris J. Brown, Nilesh J. Samani, Anna F. Dominiczak, John Connell, John Webster, G.M. Lathrop, Mark J. Caulfield, Patricia B. Munroe	69
18	No support for linkage of chromosome 17(q21-24) to Essential Hypertension in the MRC British Genetics of Hypertension (MRC BRIGHT) Study. 2001 ·The American Journal of Human Genetics ·Jo Knight, Patricia B. Munroe, (unknown), (unknown), J Pembroke, (unknown), Mark J. Brown, N. J. Samani, Nigel Benjamin, Martin Farrall, D Clayton, Peter J. Ratcliffe, Jennifer Webster, M Lathrop, Anna F. Dominiczak, J Connell, Mark J. Caulfield	1
19	Cardiovascular risk factors in a cohort of 30 000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 2001 ·Journal of Human Hypertension ·(unknown), (unknown), Mark J. Caulfield, N. Poulter	3
20	A new tool for checks of data precision within the MRC British genetics of hypertension study 2000 ·Journal of Hypertension ·Mark J. Caulfield, (unknown), J Pembroke, Patricia B. Munroe, Martin Farrall, Anna F. Dominiczak, (unknown), Peter J. Ratcliffe, Melissa J. Lathrop, Jeffrey Dean Webster, (unknown), (unknown), M.D. Brown, N. J. Samani, J Connell	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact